Unknown

Dataset Information

0

Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.


ABSTRACT: Time-dependent inactivation (TDI) of cytochrome P450s (CYPs) is a leading cause of clinical drug-drug interactions (DDIs). Current methods tend to overpredict DDIs. In this study, a numerical approach was used to model complex CYP3A TDI in human-liver microsomes. The inhibitors evaluated included troleandomycin (TAO), erythromycin (ERY), verapamil (VER), and diltiazem (DTZ) along with the primary metabolites N-demethyl erythromycin (NDE), norverapamil (NV), and N-desmethyl diltiazem (NDD). The complexities incorporated into the models included multiple-binding kinetics, quasi-irreversible inactivation, sequential metabolism, inhibitor depletion, and membrane partitioning. The resulting inactivation parameters were incorporated into static in vitro-in vivo correlation (IVIVC) models to predict clinical DDIs. For 77 clinically observed DDIs, with a hepatic-CYP3A-synthesis-rate constant of 0.000?146 min-1, the average fold difference between the observed and predicted DDIs was 3.17 for the standard replot method and 1.45 for the numerical method. Similar results were obtained using a synthesis-rate constant of 0.000?32 min-1. These results suggest that numerical methods can successfully model complex in vitro TDI kinetics and that the resulting DDI predictions are more accurate than those obtained with the standard replot approach.

SUBMITTER: Yadav J 

PROVIDER: S-EPMC5938745 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Yadav Jaydeep J   Korzekwa Ken K   Nagar Swati S  

Molecular pharmaceutics 20180410 5


Time-dependent inactivation (TDI) of cytochrome P450s (CYPs) is a leading cause of clinical drug-drug interactions (DDIs). Current methods tend to overpredict DDIs. In this study, a numerical approach was used to model complex CYP3A TDI in human-liver microsomes. The inhibitors evaluated included troleandomycin (TAO), erythromycin (ERY), verapamil (VER), and diltiazem (DTZ) along with the primary metabolites N-demethyl erythromycin (NDE), norverapamil (NV), and N-desmethyl diltiazem (NDD). The c  ...[more]

Similar Datasets

| S-EPMC6458156 | biostudies-literature
| S-EPMC3716306 | biostudies-literature
| S-EPMC6496093 | biostudies-literature
| S-EPMC4538442 | biostudies-literature
| S-EPMC6152024 | biostudies-literature
| S-EPMC10196430 | biostudies-literature
| S-EPMC5869557 | biostudies-literature
| S-EPMC6150391 | biostudies-literature
| S-EPMC8604211 | biostudies-literature
| S-EPMC6386724 | biostudies-literature